DEEP-TECH BIOTECHNOLOGY & PRECISION MEDICINE

SciGeneX

From Data to Cure

Powered by Multi-Omics AI, Functional Validation & Personalized Therapies

SciGeneX is building an integrated, AI-powered precision oncology platform that bridges multi-omics intelligence with functional validation to advance personalized cancer care.

By combining AI-driven multi-omics interpretation and personalized drug recommendations with advanced tumor-on-chip systems and patient-derived tumor organoids, SciGeneX aims to move beyond computational predictions toward experimentally validated, patient-specific therapeutic strategies.

Our integrated approach is designed to guide the development of next-generation personalized treatments, including T-cell therapies such as TCR-T and CAR-T, and neoantigen-based cancer vaccines. By connecting biological discovery, functional testing, and therapeutic development, SciGeneX seeks to help address critical challenges in cancer treatment and advance more effective, durable, and individualized care, including strategies with the potential to reduce post-surgical recurrence.

“From Molecular Insights to Functionally Validated, Personalized Cancer Therapies.”

PrecisionOncoAI

From Multi-Omics to Personalized Cancer Care

An AI-powered precision oncology platform integrating multi-omics analysis, intelligent interpretation, personalized drug recommendations, and functional validation to guide the development of individualized cancer treatment strategies.

Key Capabilities:

✓ Multi-omics data integration and AI interpretation
✓ Personalized drug response prediction and recommendations
✓ Functional validation of candidate therapies
✓ Support for personalized T-cell therapies and cancer vaccines

Explore PrecisionOncoAI →

Cell Therapies

Engineering the Next Generation of Cellular Medicines

Advancing the discovery, development, and translation of next-generation cellular therapies, with a focus on precision-engineered immune cells and personalized cancer treatment approaches.

Key Capabilities:

✓ CAR-T Cell Therapy for Hematological Cancers
✓ CAR-T Cell Therapy for Solid Cancers
✓ TCR-T Cell Therapy for Solid Cancers
✓ Personalized Cancer Vaccines
✓ Tumor-Infiltrating Lymphocytes (TILs)
✓ Stem Cell Therapies (MSCs and HSCs)
✓ Induced Pluripotent Stem Cells (iPSCs) and Associated Exosomes

Explore Cell Therapies →

Diagnostic & Life Science Reagents

Native Antigens • Antibodies • Enzymes • Biospecimens

Supplying high-quality biological raw materials and reagents to support diagnostic assay development, life-science research, and precision medicine—preserving native human molecular fidelity and epitope integrity.

Key Capabilities:

1. Native Antigens

Authentically post-translationally modified human cancer antigens (e.g., CA 15-3, CA 125, CEA, CA 19-9, HE4) preserving native epitopes.

2. Antibodies

High-specificity monoclonal and polyclonal antibodies developed for diagnostic assay integration, validation, and screening.

3. Enzymes

Specialized biocatalytic and molecular enzymes optimized for diagnostic platforms and molecular biology workflows.

4. Human Biospecimens

Ethically consented, clinically characterized human biofluids and tissue specimens collected under rigorous ethical and regulatory standards.

Explore Native Antigens Catalog →

INNOVATION PHILOSOPHY

Turning Biological Complexity into Actionable Science

At SciGeneX Pharma, we reject reductionist compromises. Living biology does not operate through isolated synthetic fragments—it functions through complex glycosylation, conformational tertiary folding, and high-dimensional cellular networks. We build the definitive bridge connecting biological complexity, computational intelligence, and translational healthcare impact.

01 / NATIVE BIOLOGY

Epitopic Fidelity

Preserving post-translational modifications (PTMs) that synthetic recombinant methods strip away.

02 / CELL ENGINEERING

Translational Rigor

Closed-system bioprocessing and stringent analytical characterization for stem cells and immune cells.

03 / ARTIFICIAL INTELLIGENCE

Functional Precision

Graph neural networks predicting drug response, neoantigens, and synergistic combinations.

04 / CIRCULAR BIOECONOMY

Waste to Wisdom

Converting ethically consented surgical remnants into life-saving diagnostic calibrators and cell lines.

CORE TECHNOLOGY DOMAINS

Three Pillars of Deep-Tech Innovation

SciGeneX operates at the strategic convergence of Native Biomarkers, Advanced Cell Engineering, and AI-Driven Functional Precision Oncology.

01 BIOLOGICAL RAW MATERIALS & REAGENTS

Diagnostic & Life Science Reagents

“Native Antigens • Antibodies • Enzymes • Biospecimens”

Core Capabilities & Product Classes

1. Native Antigens

Authentically post-translationally modified human cancer antigens (e.g., CA 15-3, CA 125, CEA, CA 19-9, HE4) preserving native epitopes.

2. Antibodies

High-specificity monoclonal and polyclonal antibodies developed for diagnostic assay integration, validation, and screening.

3. Enzymes

Specialized biocatalytic and molecular enzymes optimized for diagnostic platforms and molecular biology workflows.

4. Human Biospecimens

Ethically consented, clinically characterized human biofluids and tissue specimens collected under rigorous ethical and regulatory standards.

Documented Analytical Attributes: Intact physiological 3D conformational epitopes and complex branching human glycosylation. Analytical purity >95% by SDS-PAGE on characterized release lots with commutability against WHO reference standards. Core panel: CA 15-3, CA 125, CEA, CA 19-9, and HE4 (supplied as research-use-only and IVD-development raw materials subject to product availability).

Why Native Outperforms Recombinant → Explore Native Antigens Catalog

02 ADVANCED CELL THERAPY

Cell Therapies

“Engineering the next generation of cellular medicines.”

Advancing the discovery, development, and translation of next-generation cellular therapies, with a focus on precision-engineered immune cells and personalized cancer treatment approaches.

Therapeutic Modalities & Capabilities

✓ CAR-T Cell Therapy for Hematological Cancers
✓ CAR-T Cell Therapy for Solid Cancers
✓ TCR-T Cell Therapy for Solid Cancers
✓ Personalized Cancer Vaccines
✓ Tumor-Infiltrating Lymphocytes (TILs)
✓ Stem Cell Therapies (MSCs and HSCs)
✓ Induced Pluripotent Stem Cells (iPSCs) and Associated Exosomes

Development Pathways & Readiness: Closed-system bioprocessing and cellular engineering. Program SGX-CELL-01 (Closed-System Autologous T-Cell Bioprocessing: TRL 5 - Pilot Validation) • Program SGX-CELL-02 (WJ-MSC Platform: TRL 4 - Proof of Concept).

Note: Research and technology development division. Pre-clinical and investigational use.

Explore Cell Technologies

03 FLAGSHIP AI PLATFORM

PrecisionOncoAI

“From multi-omics to personalized cancer care.”

Integrated Innovation Pathway

✓ Multi-omics data integration and AI interpretation
✓ Personalized drug response prediction & recommendations
✓ Functional validation of candidate therapies (3D Organoids)
✓ Support for personalized T-cell therapies & cancer vaccines

Platform Workflow & Evidence-Based TRL: Multi-Omics → AI Interpretation → Personalized Recommendations → Functional Validation. Program SGX-AI-01 (Neoantigen Prediction Engine: TRL 6 - Validation) • Program SGX-AI-02 (Functional Ex-Vivo Drug Sensitivity AI Matrix: TRL 4 - Proof of Concept).

Research & clinical decision support intelligence. No autonomous diagnosis claims.

Explore PrecisionOncoAI Platform

SCIENTIFIC RIGOR

The Native Advantage: Why Biology Matters

Recombinant antigens generated in bacterial or rodent host systems frequently fail to reproduce authentic human tertiary folding and branching glycosylation. SciGeneX preserves native human biology.

Biological Parameter	SciGeneX Native Human Antigens	Standard Recombinant / Synthetic Antigens	Diagnostic & Clinical Impact
Post-Translational Modifications (PTMs)	100% Authentic Human PTMs (Phosphorylation, Sulfation, Acetylation)	Absent or non-human prokaryotic/insect PTM patterns	Ensures clinical antibody binding affinity matches real patient serum exactly
Glycosylation & Glycan Branching	Authentic human N- and O-glycans, sialic acid caps	High-mannose or non-human carbohydrate structures	Crucial for mucin markers (CA 125, CA 15-3, CA 19-9) where epitopes are glycan-dependent
3D Conformational Epitopes	Native physiological folding preserved under non-denaturing chromatography	Frequent misfolding, aggregation, and truncated domain folding	Eliminates false negatives in conformational monoclonal antibody assays
Patient Biological Heterogeneity	Derived from pooled clinical biospecimens reflecting disease diversity	Monoclonal clonal homogeneity from a single synthetic vector	Broad dynamic range calibration across diverse patient populations
Immunoassay Cross-Reactivity	Extremely low false positives; verified matrix commutability	High background noise due to non-specific antibody adherence	Standardizes IVD assay performance on Roche, Abbott, and Siemens analyzers

FLAGSHIP DEEP-TECH PLATFORM

PrecisionOncoAI Architecture

AI-Powered Integrated Functional Precision Oncology Platform: Uniting Multi-Omics, Deep Neural Networks, Ex-Vivo Validation, and Therapeutic Recommendation.

EX-VIVO BIOLOGICAL SYSTEMS • PHASE 03

Functional Validation Capabilities

Phase 03 Validation Engine

Bridging in-silico computational predictions with empirical biological confirmation through microfluidic systems, patient-derived models, and cellular response profiling to assess personalized therapeutic vulnerabilities.

★

Patient-Derived Microfluidic Tumor-on-Chip-Based Drug Validation (ToC)

Core Capability

Functional evaluation of candidate anticancer drugs using patient-derived tumor models in microfluidic tumor-on-chip systems to support personalized drug-response assessment and precision oncology research.

Patient-Derived Organoids (PDO)

Cultivation of 3D patient primary micro-tissues preserving histological architecture and clonal heterogeneity for high-throughput perturbation screens.

High-Throughput Cell Perturbation

Automated multi-well cytotoxicity, apoptosis kinetics, and metabolic viability profiling across targeted compound and combinatorial libraries.

Multiplex Immune Profiling

Ex-vivo autologous immune co-cultures and spectral flow cytometry evaluating T-cell activation, exhaustion markers, and neoepitope cytotoxicity.

Target CRISPR Knockout Validation

Arrayed and pooled CRISPR-Cas9 essentiality screening to functionally validate predicted synthetic lethal dependencies and target druggability.

Ex-Vivo Drug Sensitivity Testing

Empirical dose-response curve generation and IC50 determination to prioritize candidate therapeutic regimens for clinical decision support.

TRANSLATIONAL VALUE PATHWAY

From Biology to Impact

An interactive scientific journey tracing how raw biological materials are transformed through molecular characterization, computational biology, and cellular assays into clinical translation.

CIRCULAR BIOECONOMY

Waste to Wealth. Waste to Wisdom.

How ethically sourced biomedical remnants—historically discarded as clinical bio-waste—are converted into life-saving biological intelligence, native antigens, and precision healthcare solutions.

Circular Bioeconomy SciGeneX Closed Loop

PHASE 01

Biomedical Materials

Consented surgical remnants, fluids, and non-embryonic tissues salvaged from clinical partner institutions subject to Institutional Ethics Committee (IEC) clearance and patient consent.

Ethical, Regulatory & Biosafety Safeguards

✓ IEC / IRB Review: Institutional Ethics Committee approval across all clinical collection sites.

✓ Informed Consent: Explicit, voluntary, anonymized patient informed consent under ICMR guidelines.

✓ Pathogen Screening: Full BSL-2 quarantine testing for viral markers (HIV, HBV, HCV, Syphilis).

✓ Chain of Custody: Continuous temperature-logged barcode serialization from clinic to laboratory.

MULTIDISCIPLINARY INFRASTRUCTURE

Interactive Technology Capabilities Map

Explore SciGeneX’s proprietary platforms, instrumentation, and clinical laboratory methodologies across 10 specialized life-science domains.

COMMERCIAL PRODUCTS & SPECIFICATIONS

Native Antigens Catalog

Authentic native human antigens preserved with physiological post-translational modifications, conformational epitopes, and complex glycosylation for diagnostic assay manufacturers, clinical research, and precision oncology.

🔍

Showing: 29 markers

INNOVATION PIPELINE

Translational Research & Pipeline Tracker

Tracking our programs across PrecisionOncoAI, microfluidic Tumor-on-Chip, Cell Therapies, and Native Antigens from initial biological discovery to validated clinical commercialization.

Stages: Discovery (1-2) → PoC (3-4) → Validation (5-6) → Product Dev (7-8) → Commercial (9)

LEADERSHIP & COMPOSITION

The Multidisciplinary Scientific Synergy

True deep-tech breakthroughs cannot occur in isolated silos. SciGeneX combines molecular biologists, medical oncologists, machine learning engineers, and bio-business strategists under a unified translational mission.

Scientists

Specialists in protein purification, mass-spectrometry, and cell culture.

Clinicians

Surgical oncologists and molecular pathologists ensuring clinical relevance.

AI Specialists

Graph neural network modelers and bioinformatics pipeline architects.

Business Strategists

CDMO veterans and regulatory experts navigating global commercialization.

STRATEGIC ALLIANCES

Partner With SciGeneX

We collaborate with global diagnostic manufacturers, biopharma leaders, premier clinical institutions, and deep-tech healthcare investors to accelerate biological innovation into patient care.

Diagnostic Kit Manufacturers

Industry Challenge

False positives and assay drift from un-glycosylated synthetic calibrators.

SciGeneX Solution

Bulk supply of native human tumor markers (CA 125, CA 15-3, CA 19-9, CEA) with batch-to-batch commutability.

Pharma & Biotech Companies

Industry Challenge

High attrition rates during target discovery and late-stage clinical trials.

SciGeneX Solution

Ex-vivo patient-derived organoid testing and companion diagnostic (CDx) co-development.

Hospitals & Cancer Centers

Industry Challenge

Surgical specimens discarded without generating research value or patient benefit.

SciGeneX Solution

Closed-loop circular bioeconomy biobanking and PrecisionOncoAI pilot studies.

Academic & Research Labs

Industry Challenge

Lack of access to authentic human clinical-grade native antigen standards.

SciGeneX Solution

RUO antigen aliquots, joint grant sponsorship, and peer-reviewed collaborative research.

Cell Therapy CDMOs

Industry Challenge

Complex process validation and variable expansion kinetics in primary immune cells.

SciGeneX Solution

Standardized closed-system bioprocessing protocols and 16-color flow cytometry characterization.

Healthcare Investors & Funds

Industry Challenge

Seeking defensible, high-barrier deep-tech biotechnology ventures in India.

SciGeneX Solution

Strategic equity investment in proprietary multi-omics platforms with global export market potential.

DIRECT ALLIANCE INTAKE

Discuss a Collaboration

Initiate a confidential discussion with our Scientific Advisory & Business Development committee.

Full Name & Title *

Corporate Email Address *

Organization / Institution Name *

Organization Classification *

Primary Technology / Product of Interest *

Project Scope & Technical Requirements

Request mutual Confidential Disclosure Agreement (CDA / NDA) prior to technical review.

SCIENTIFIC DISCOURSE

News & Research Insights

Technical publications, platform whitepapers, and thought leadership from the SciGeneX scientific team.

WHITEPAPER • OCTOBER 2026

Preserving Native Glycoforms: Why Recombinant Antigens Fall Short in Ovarian Cancer Diagnostics

A deep technical study comparing post-translational glycosylation between cell-line recombinant proteins and native clinical CA 125, demonstrating superior antibody affinity.

PLATFORM ARCHITECTURE • SEPTEMBER 2026

PrecisionOncoAI: Bridging High-Dimensional Multi-Omics to the Oncology Clinic

How graph neural networks integrate patient genomics, mass-spec proteomics, and organoid viability curves into interpretable clinical decision support.

CIRCULAR BIOECONOMY • AUGUST 2026

Waste to Wealth, Waste to Wisdom: Ethical Biobanking for Next-Gen Healthcare in India

Establishing ethical consent, ICMR guideline compliance, and high-yield bioprocessing to repurpose surgical residues into high-value diagnostic calibrators.